Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.85 USD | +0.25% | +5.05% | +2.09% |
03-20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
02-27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.09% | 1.79B | C | ||
+0.89% | 12.95B | B+ | ||
-7.57% | 7.84B | B- | ||
+1.61% | 5.5B | B | ||
+0.93% | 4.61B | C | ||
+7.81% | 4.61B | C | ||
-49.03% | 3.4B | D+ | ||
+9.21% | 2.66B | - | - | |
-14.59% | 2.08B | B- | ||
-11.63% | 1.72B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYGN Stock
- Ratings Myriad Genetics, Inc.